384 related articles for article (PubMed ID: 33564837)
41. Mechanisms of vasodilation to PTH 1-84, PTH 1-34, and PTHrP 1-34 in rat bone resistance arteries.
Benson T; Menezes T; Campbell J; Bice A; Hood B; Prisby R
Osteoporos Int; 2016 May; 27(5):1817-26. PubMed ID: 26733378
[TBL] [Abstract][Full Text] [Related]
42. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.
Tay D; Cremers S; Bilezikian JP
Br J Clin Pharmacol; 2018 Feb; 84(2):252-267. PubMed ID: 29049872
[TBL] [Abstract][Full Text] [Related]
43. Endogenous ligand recognition and structural transition of a human PTH receptor.
Kobayashi K; Kawakami K; Kusakizako T; Miyauchi H; Tomita A; Kobayashi K; Shihoya W; Yamashita K; Nishizawa T; Kato HE; Inoue A; Nureki O
Mol Cell; 2022 Sep; 82(18):3468-3483.e5. PubMed ID: 35932760
[TBL] [Abstract][Full Text] [Related]
44. Altered Signaling and Desensitization Responses in PTH1R Mutants Associated with Eiken Syndrome.
Portales-Castillo I; Dean T; Cheloha RW; Creemer BA; Vilardaga JP; Savransky S; Khatri A; Jüppner H; Gardella TJ
Commun Biol; 2023 Jun; 6(1):599. PubMed ID: 37268817
[TBL] [Abstract][Full Text] [Related]
45. Cyclic AMP formation in rat bone and kidney cells is stimulated equally by parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34.
Blind E; Raue F; Knappe V; Schroth J; Ziegler R
Exp Clin Endocrinol; 1993; 101(3):150-5. PubMed ID: 8223983
[TBL] [Abstract][Full Text] [Related]
46. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
Augustine M; Horwitz MJ
Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
[TBL] [Abstract][Full Text] [Related]
47. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.
Dean T; Vilardaga JP; Potts JT; Gardella TJ
Mol Endocrinol; 2008 Jan; 22(1):156-66. PubMed ID: 17872377
[TBL] [Abstract][Full Text] [Related]
48. Sex-Specific Differences in G
Swami S; Johnson J; Vecchi LA; Kim MJ; Lanske B; Johnson RW; Wu JY
JBMR Plus; 2022 Dec; 6(12):e10695. PubMed ID: 36530190
[TBL] [Abstract][Full Text] [Related]
49. Receptors for PTH and PTHrP: their biological importance and functional properties.
Mannstadt M; Jüppner H; Gardella TJ
Am J Physiol; 1999 Nov; 277(5):F665-75. PubMed ID: 10564229
[TBL] [Abstract][Full Text] [Related]
50. Bone Remodeling and Modeling: Cellular Targets for Antiresorptive and Anabolic Treatments, Including Approaches Through the Parathyroid Hormone (PTH)/PTH-Related Protein Pathway.
Martin TJ; Seeman E
Neurospine; 2023 Dec; 20(4):1097-1109. PubMed ID: 38171279
[TBL] [Abstract][Full Text] [Related]
51. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
[TBL] [Abstract][Full Text] [Related]
52. Activation of the receptor for parathyroid hormone and parathyroid hormone related protein induces apoptosis via the extrinsic and intrinsic signaling pathway.
Müller M; Gagiannis S; Nawroth PP; Brune M; Schilling T
Int J Mol Med; 2009 Sep; 24(3):373-80. PubMed ID: 19639230
[TBL] [Abstract][Full Text] [Related]
53. PTH1R translocation to primary cilia in mechanically-stimulated ostecytes prevents osteoclast formation via regulation of CXCL5 and IL-6 secretion.
Tirado-Cabrera I; Martin-Guerrero E; Heredero-Jimenez S; Ardura JA; Gortázar AR
J Cell Physiol; 2022 Oct; 237(10):3927-3943. PubMed ID: 35933642
[TBL] [Abstract][Full Text] [Related]
54. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.
Plotkin H; Gundberg C; Mitnick M; Stewart AF
J Clin Endocrinol Metab; 1998 Aug; 83(8):2786-91. PubMed ID: 9709948
[TBL] [Abstract][Full Text] [Related]
55. Conditionally immortalized murine osteoblasts lacking the type 1 PTH/PTHrP receptor.
Divieti P; Lanske B; Kronenberg HM; Bringhurst FR
J Bone Miner Res; 1998 Dec; 13(12):1835-45. PubMed ID: 9844101
[TBL] [Abstract][Full Text] [Related]
56. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells.
van der Horst G; Farih-Sips H; Löwik CW; Karperien M
J Bone Miner Res; 2005 Dec; 20(12):2233-44. PubMed ID: 16294276
[TBL] [Abstract][Full Text] [Related]
57. Expression of parathyroid hormone-related protein in ameloblastomas.
Ohtsuru M
Tokai J Exp Clin Med; 2005 Dec; 30(4):233-9. PubMed ID: 16482944
[TBL] [Abstract][Full Text] [Related]
58. Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.
Sato T; Verma S; Khatri A; Dean T; Goransson O; Gardella TJ; Wein MN
JBMR Plus; 2021 May; 5(5):e10441. PubMed ID: 33977197
[TBL] [Abstract][Full Text] [Related]
59. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development.
Amizuka N; Karaplis AC; Henderson JE; Warshawsky H; Lipman ML; Matsuki Y; Ejiri S; Tanaka M; Izumi N; Ozawa H; Goltzman D
Dev Biol; 1996 Apr; 175(1):166-76. PubMed ID: 8608863
[TBL] [Abstract][Full Text] [Related]
60. Ligand binding and signalling pathways of PTH receptors in sea bream (Sparus auratus) enterocytes.
Rotllant J; Guerreiro PM; Redruello B; Fernandes H; Apolónia L; Anjos L; Canario AV; Power DM
Cell Tissue Res; 2006 Feb; 323(2):333-41. PubMed ID: 16189716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
